SCINOPHARM TAIWAN LTD

Overview

SCINOPHARM TAIWAN LTD is an active pharmaceutical ingredient (API) supplier with 71 active FDA Type II Drug Master Files, covering ABEMACICLIB; ALECTINIB HYDROCHLORIDE; ALPELISIB; ANASTROZOLE USP; APIXABAN; APREMILAST.

API / Drug Master Files

SCINOPHARM TAIWAN LTD holds 71 active (85 total) FDA Type II Drug Master Files — identifying it as an active-substance / API supplier. Type II DMFs are filed with the FDA to support the use of an active pharmaceutical ingredient in drug applications.

• ALECTINIB HYDROCHLORIDEActive2025-12-29
• SEMAGLUTIDE FULL SIDE CHAINActive2025-12-10
• OLAPARIB (FORM A)Active2025-09-26
• ABEMACICLIBActive2025-06-27
• TUCATINIBActive2025-03-26
• ALPELISIBActive2024-10-29
• NELARABINEActive2023-11-29
• ENZALUTAMIDEActive2023-08-28
• CEDAZURIDINEActive2023-07-03
• APIXABANActive2022-12-30
• LIRAGLUTIDEActive2022-05-19
• OSIMERTINIB MESYLATEActive2021-12-24
• ELAGOLIX SODIUMActive2021-03-31
• IVACAFTORActive2020-12-28
• LIFITEGRASTActive2020-12-28

Showing 15 of 85 Drug Master Files.

FDA compliance signals

No FDA recalls, Warning Letters, or Form 483 observations are linked to SCINOPHARM TAIWAN LTD in our records. PharmaTek screens the full directory against live FDA enforcement data.